Neel Nayan Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 26-07-2024
- Paid Up Capital ₹ 1.26 Cr
as on 26-07-2024
- Company Age 35 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.00 Cr
as on 26-07-2024
- Satisfied Charges ₹ 5.13 M
as on 26-07-2024
- Revenue 3.25%
(FY 2023)
- Profit -8.32%
(FY 2023)
- Ebitda 13.78%
(FY 2023)
- Net Worth 601.91%
(FY 2023)
- Total Assets 42.62%
(FY 2023)
About Neel Nayan Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.26 Cr.
The company currently has active open charges totaling ₹9.00 Cr. The company has closed loans amounting to ₹5.13 M, as per Ministry of Corporate Affairs (MCA) records.
Virdeepsinh Sarvaiya and Monica Pant serve as directors at the Company.
- CIN/LLPIN
U24231GJ1989PTC013031
- Company No.
013031
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Nov 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandevi, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Neel Nayan Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Virdeepsinh Sarvaiya  | Director | 31-Jul-2019 | Current |
| Monica Pant | Director | 31-Jul-2019 | Current |
Financial Performance of Neel Nayan Pharma.
Neel Nayan Pharma Pvt Ltd, for the financial year ended 2023, experienced modest growth in revenue, with a 3.25% increase. The company also saw a slight decrease in profitability, with a 8.32% decrease in profit. The company's net worth Soared by an impressive increase of 601.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neel Nayan Pharma?
In 2023, Neel Nayan Pharma had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rinica Pharma Private LimitedActive 10 years 4 monthsVirdeepsinh Sarvaiya and Monica Pant are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 23 Jun 2023 | ₹5.00 Cr | Open |
Axis Bank Limited Creation Date: 04 Jun 2019 | ₹4.00 Cr | Open |
Bank Of Baroda Creation Date: 30 Apr 2006 | ₹0.50 M | Satisfied |
How Many Employees Work at Neel Nayan Pharma?
Neel Nayan Pharma has a workforce of 22 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neel Nayan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neel Nayan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
